<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) have rarely been reported after treatment with <z:chebi fb="0" ids="33838">nucleoside</z:chebi> analogues, and mainly in patients who have also received <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>We report a patient who developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with ring sideroblasts) after treatment with pentostatin (deoxycoformycin) alone </plain></SENT>
</text></document>